Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025European PsychiatryOpen Access

Investigation of cytokine imbalance in schizophrenia, assessment of the possible role of serum cytokine levels in predicting treatment response, prognosis and psychotic relapses

View Full Paper
Ask AI
Bookmark
Share

Authors

KBKatharine BodnarLHLevente HermánRZR. I. Zsigmond

Discussion

Loading...

Member takes

Overview

Investigation reveals higher MCP-1 levels in schizophrenia, indicating potential biomarkers for treatment response and prognosis.

Key Points

  • Elevated plasma levels of MCP-1 correlate with psychotic relapses in patients with schizophrenia.
  • Analysis showed no significant differences in several inflammatory cytokines between patients and healthy controls.
  • Cytokine levels were assessed using the Cytometric Bead Array method during hospital admission.
  • Further studies are needed to explore mechanisms that link cytokines to schizophrenia progression.

Cite This Study

Bodnar et al. (2025) studied this question.

synapsesocial.com/papers/68d4507d31b076d99fa580cdhttps://doi.org/10.1192/j.eurpsy.2025.618
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Investigation of cytokine imbalance in schizophrenia, assessment of the possible role of serum cytokine levels in predicting treatment response, prognosis and psychotic relapses2024
  2. 2Plasma concentrations of IL-8, IFN-γ and IL-1β in schizophrenia patients with subgroup analysis of first episode drug naïve patients2024
  3. 3Changes in inflammatory parameters and antioxidants and their impact on clinical symptoms, including cognitive functions, in patients with schizophrenia - scoping review2024
  4. 4Evaluation of IL-1β, IL-6, and inflammatory markers during exacerbation and after antipsychotic treatment in drug-free schizophrenia patients2025 · 3 citations
  5. 5Immune factors associated with prominent negative symptoms and disease severity in schizophrenia2024